BMI View: Lithuania’s pharmaceutical and healthcare market represents a modest prospect for investment
from multinational firms. Increasing demand due to a rising burden of chronic disease will translate to an
increase in sales; however, fiscal policies and the small size of the market will limit revenue earning
opportunities.
Headline Expenditure Projections
? Pharmaceuticals: EUR601mn (USD806mn) in 2014 to EUR616mn (USD677mn) in 2015; +2.4% in
local currency terms and -16.0% in US dollar terms. Forecast revised downwards from Q215.
? Healthcare: EUR2.14bn (USD2.87bn) in 2014 to EUR2.14bn (USD2.36bn) in 2015; +0.1% in local
currency terms and -17.8% in US dollar terms. Forecast revised downwards from Q215.

Table of Contents

BMI Industry View 7
Table: Headline Pharmaceuticals & Healthcare Forecasts (Lithuania 2013-2019) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Lithuania 2013-2019) 12
Healthcare Market Forecast 13
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Lithuania 2013-2019) 15
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Lithuania 2013-2019) 15
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Lithuania 2013-2019) 15
Prescription Drug Market Forecast 16
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Lithuania 2011-2019) 17
Patented Drug Market Forecast 18
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Lithuania 2011-2019) 19
Generic Drug Market Forecast 20
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Lithuania 2013-2019) 21
OTC Market Forecast 22
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Lithuania 2013-2019) 23
Pharmaceutical Trade Forecast 24
Table: Pharmaceutical Trade Data And Forecasts (Lithuania 2013-2019) 25
Table: Pharmaceutical Trade Data And Forecasts local currency (Lithuania 2013-2019) 26
Industry Risk Reward Index 27
Central And Eastern Europe Risk/Reward Index - Q1 2016 27
Lithuania Risk/Reward Index 34
Rewards 34
Risks 34
Regulatory Review 36
Intellectual Property Regime 39
Pricing Regime 39
Table: Wholesale Mark-Ups For Reimbursed And Non-Reimbursed Medicines 40
Reimbursement Regime 41
Table: Retail Mark-Ups For Reimbursed And Non-Reimbursed Medicines 42
Market Overview 44
Healthcare Sector 45
Table: Healthcare Resources (Lithuania 2009-2014) 46
Table: Healthcare Personnel (Lithuania 2009-2014) 46
Table: Healthcare Activity (Lithuania 2009-2014) 47
Research & Development 48
Clinical Trials 50
Epidemiology 51
Table: Leading Causes of Death, 2005-2013 51
Table: Incidence of HIV & AIDS, 2002-2010 53
Competitive Landscape 54
Research-Based Industry 54
Table: Members of the Innovative Pharmaceutical Industry Association (IFPA) 54
Table: Multinational Market Activity 55
Generic Drugmakers 55
Pharmaceutical Distribution 56
Pharmaceutical Retail Sector 57
Company Profile 59
Valentis 59
Sanitas (Valeant) 61
Sicor Biotech (Teva) 64
Demographic Forecast 67
Table: Population Headline Indicators (Lithuania 1990-2025) 68
Table: Key Population Ratios (Lithuania 1990-2025) 68
Table: Urban/Rural Population & Life Expectancy (Lithuania 1990-2025) 69
Table: Population By Age Group (Lithuania 1990-2025) 69
Table: Population By Age Group % (Lithuania 1990-2025) 70
Glossary 72
Methodology 74
Pharmaceutical Expenditure Forecast Model 74
Healthcare Expenditure Forecast Model 74
Notes On Methodology 75
Risk/Reward Index Methodology 76
Index Overview 77
Table: Pharmaceutical Risk/Reward Index Indicators 77
Indicator Weightings 78

List of Tables

Table: Headline Pharmaceuticals & Healthcare Forecasts (Lithuania 2013-2019)
Table: Pharmaceutical Sales, Historical Data And Forecasts (Lithuania 2013-2019)
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Lithuania 2013-2019)
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Lithuania 2013-2019)
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Lithuania 2013-2019)
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Lithuania 2011-2019)
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Lithuania 2011-2019)
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Lithuania 2013-2019)
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Lithuania 2013-2019)
Table: Pharmaceutical Trade Data And Forecasts (Lithuania 2013-2019)
Table: Pharmaceutical Trade Data And Forecasts local currency (Lithuania 2013-2019)
Table: Wholesale Mark-Ups For Reimbursed And Non-Reimbursed Medicines
Table: Retail Mark-Ups For Reimbursed And Non-Reimbursed Medicines
Table: Healthcare Resources (Lithuania 2009-2014)
Table: Healthcare Personnel (Lithuania 2009-2014)
Table: Healthcare Activity (Lithuania 2009-2014)
Table: Leading Causes of Death, 2005-2013
Table: Incidence of HIV & AIDS, 2002-2010
Table: Members of the Innovative Pharmaceutical Industry Association (IFPA)
Table: Multinational Market Activity
Table: Population Headline Indicators (Lithuania 1990-2025)
Table: Key Population Ratios (Lithuania 1990-2025)
Table: Urban/Rural Population & Life Expectancy (Lithuania 1990-2025)
Table: Population By Age Group (Lithuania 1990-2025)
Table: Population By Age Group % (Lithuania 1990-2025)
Table: Pharmaceutical Risk/Reward Index Indicators